These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 33655683)

  • 21. Rabbit-ATG or basiliximab induction for rapid steroid withdrawal after renal transplantation (Harmony): an open-label, multicentre, randomised controlled trial.
    Thomusch O; Wiesener M; Opgenoorth M; Pascher A; Woitas RP; Witzke O; Jaenigen B; Rentsch M; Wolters H; Rath T; Cingöz T; Benck U; Banas B; Hugo C
    Lancet; 2016 Dec; 388(10063):3006-3016. PubMed ID: 27871759
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High-dose mizoribine combined with calcineurin inhibitor (cyclosporine or tacrolimus), basiliximab and corticosteroids for renal transplantation: A Japanese multicenter study.
    Nishioka T; Yoshimura N; Ushigome H; Watarai Y; Nishimura K; Akioka K; Nakamura N; Kawakita M; Yuzawa K; Nakatani T
    Int J Urol; 2018 Feb; 25(2):141-145. PubMed ID: 29068092
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Early steroid withdrawal therapy in renal transplant recipients: a steroid-free sirolimus and CellCept-based calcineurin inhibitor-minimization protocol.
    Jaber JJ; Feustel PJ; Elbahloul O; Conti AD; Gallichio MH; Conti DJ
    Clin Transplant; 2007; 21(1):101-9. PubMed ID: 17302598
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acute pancreatitis due to tacrolimus in kidney transplant and review of the literature.
    Liu XH; Chen H; Tan RY; Luo C
    J Clin Pharm Ther; 2021 Feb; 46(1):230-235. PubMed ID: 32949156
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The transmission of donor-derived malignant melanoma to a renal allograft recipient.
    Milton CA; Barbara J; Cooper J; Rao M; Russell C; Russ G
    Clin Transplant; 2006; 20(5):547-50. PubMed ID: 16968479
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Induction Therapies in Live Donor Kidney Transplantation on Tacrolimus and Mycophenolate With or Without Steroid Maintenance.
    Tanriover B; Zhang S; MacConmara M; Gao A; Sandikci B; Ayvaci MU; Mete M; Tsapepas D; Rajora N; Mohan P; Lakhia R; Lu CY; Vazquez M
    Clin J Am Soc Nephrol; 2015 Jun; 10(6):1041-9. PubMed ID: 25979971
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hypernatremia and acute pancreatitis in chronic kidney disease: back to the salt mines. Questions.
    de Tersant M; Kwon T; Macher MA; Maisin A; Deschênes G; Niel O
    Pediatr Nephrol; 2018 Jul; 33(7):1155-1156. PubMed ID: 29067525
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Decreased acute rejection and improved renal allograft survival using sirolimus and low-dose calcineurin inhibitors without induction therapy.
    Tsai MK; Wu FL; Lai IR; Lee CY; Hu RH; Lee PH
    Int J Artif Organs; 2009 Jun; 32(6):371-80. PubMed ID: 19670189
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Conversion From Calcineurin Inhibitors to Belatacept in HLA-sensitized Kidney Transplant Recipients With Low-level Donor-specific Antibodies.
    Ulloa CE; Anglicheau D; Snanoudj R; Scemla A; Martinez F; Timsit MO; Legendre C; Sberro-Soussan R
    Transplantation; 2019 Oct; 103(10):2150-2156. PubMed ID: 30720681
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
    Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
    Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and Efficacy Outcomes 3 Years After Switching to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: Results From a Phase 2 Randomized Trial.
    Grinyó JM; Del Carmen Rial M; Alberu J; Steinberg SM; Manfro RC; Nainan G; Vincenti F; Jones-Burton C; Kamar N
    Am J Kidney Dis; 2017 May; 69(5):587-594. PubMed ID: 27889299
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Renal transplantation: can we reduce calcineurin inhibitor/stop steroids? Evidence based on protocol biopsy findings.
    Gotti E; Perico N; Perna A; Gaspari F; Cattaneo D; Caruso R; Ferrari S; Stucchi N; Marchetti G; Abbate M; Remuzzi G
    J Am Soc Nephrol; 2003 Mar; 14(3):755-66. PubMed ID: 12595513
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Experience with the use of sirolimus in liver transplantation--use in patients for whom calcineurin inhibitors are contraindicated.
    Chang GJ; Mahanty HD; Quan D; Freise CE; Ascher NL; Roberts JP; Stock PG; Hirose R
    Liver Transpl; 2000 Nov; 6(6):734-40. PubMed ID: 11084060
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevention of acute rejection with antithymocyte globulin (Thymoglobuline): its potential to reduce corticosteroids.
    Cantarovich D
    J Nephrol; 2004; 17 Suppl 8():S40-6. PubMed ID: 15599885
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acute pancreatitis in ICU secondary to treatment with tigecycline.
    Bernas Albeniz A; Aveiga Valencia DA; Etxeberria Zabala L; Zaldibar-Gerrikagoitia Bilbao J; Aguilera Celorrio L
    Rev Esp Anestesiol Reanim; 2017 Jan; 64(1):46-49. PubMed ID: 27609674
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Single-center experience with tacrolimus-based immunosuppressive regimens in renal transplantation.
    Abou-Jaoude MM; Almawi WY
    Mol Immunol; 2003 Jul; 39(17-18):1067-72. PubMed ID: 12835078
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
    Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-thymocyte globulin versus basiliximab induction in renal transplant recipients: Long-term outcome.
    Kesiraju S; Paritala P; Rao Ch UM; Athmakuri SM; Reddy VS; Sahariah S
    Saudi J Kidney Dis Transpl; 2014 Jan; 25(1):9-15. PubMed ID: 24434376
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of mycophenolate mofetil on recurrent rejection in kidney transplant patients.
    Vasquez EM; Sifontis NM; Pollak R; Benedetti E
    Clin Transplant; 2001 Aug; 15(4):253-7. PubMed ID: 11683819
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of prophylaxis with low-dose anti-thymocyte globulin on prevention of acute kidney allograft rejection.
    Khosroshahi HT; Tubbs RS; Shoja MM; Ghafari A; Noshad H; Ardalan MR
    Transplant Proc; 2008; 40(1):137-9. PubMed ID: 18261569
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.